GlassScriptPhysician profile
Andre Rehaun Holmes
NPI 1457425480
$8,175.66
in general payments reported to CMS, 2019-2025
38 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.00 · 2020: $236 · 2021: $149 · 2022: $321 · 2023: $1,552 · 2024: $4,064 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312 · Consulting Fee: $2,000 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,312.14 |
| Consulting Fee | $2,000.00 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $2,028.19 | 2023-2024 | Smartvest |
| Glaxosmithkline, LLC. | $1,248.91 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,191.79 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $517.61 | 2021-2025 | |
| Amgen INC. | $356.25 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $332.70 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.01 | 2021-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $220.01 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $213.81 | 2024-2025 | |
| Mylan Specialty L.P. | $212.19 | 2019-2024 | Yupelri |
| Baxter Healthcare | $167.59 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $163.03 | 2020-2025 | |
| Insmed, INC. | $138.42 | 2024-2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $134.64 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $107.00 | 2024-2025 | Dupixent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $80.50 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Axsome Therapeutics, INC. | $72.10 | 2023-2025 | Sunosi |
| Inari Medical, INC. | $69.94 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $59.89 | 2023-2024 | (Ak6) Vest Therapy |
| Vapotherm INC | $56.21 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $44.40 | 2024 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $43.79 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.87 | 2024-2025 | Glassia |
| Paratek Pharmaceuticals, INC. | $34.42 | 2025 | Nuzyra |
| Medivance, INC. | $30.70 | 2020 | |
| Resmed Corp | $29.73 | 2023-2024 | |
| Tactile Systems Technology INC | $29.59 | 2024 | Flexitouch Plus, Entre Plus |
| Avadel Cns Pharmaceuticals, LLC | $25.91 | 2024 | Lumryz |
| Molnlycke Health Care US, LLC | $24.56 | 2020 | |
| Covis Pharma Gmbh | $22.78 | 2022 | |
| Vifor Pharma, INC. | $20.61 | 2024 | Zemaira |
| Novartis Pharmaceuticals Corporation | $20.42 | 2025 | |
| Merck Sharp & Dohme LLC | $19.96 | 2023 | |
| Pfizer INC. | $19.46 | 2023 | |
| Lilly USA, LLC | $19.46 | 2025 | Zepbound |
| Kaleo, INC. | $17.27 | 2020 | |
| Hikma Pharmaceuticals USA | $15.95 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.